TY - JOUR
T1 - Distinct progression patterns across Parkinson disease clinical subtypes
AU - Myers, Peter S.
AU - Jackson, Joshua J.
AU - Clover, Amber K.
AU - Lessov-Schlaggar, Christina N.
AU - Foster, Erin R.
AU - Maiti, Baijayanta
AU - Perlmutter, Joel S.
AU - Campbell, Meghan C.
N1 - Funding Information:
Erin R. Foster is funded by the National Institutes of Health (NIA R21AG063974, NIA R01AG065214, NIDDK R01DK064832) and the Advanced Research Center of the Greater St. Louis Chapter of the American Parkinson Disease Association.
Funding Information:
Baijayanta Maiti received funding from the National Center for Advancing Translational Sciences of the National Institutes of Health KL2 TR002346, American Academy of Neurology and American Brain Foundation Clinical Research Training Fellowship in Parkinson’s disease, Parkinson Study Group/Parkinson’s Disease Foundation Mentored Clinical Research Award, Greater St. Louis Chapter of American Parkinson Disease Association and the Jo Oertli fund. He has received compensation for reviewing grants as a member of the Parkinson Study Group mentoring committee.
Funding Information:
The authors gratefully acknowledge the funding support provided by grants from NINDS (NS097437, NS075321, NS41509, NS058714, NS48924, P30 NS048056) and NIH NCRR (UL1RR024992); American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; Oertli Fund; Paula & Rodger Riney Fund; Barnes Jewish Hospital Foundation (BJHF) (Elliot Stein Family Fund & PD Research Fund) for this work.
Funding Information:
Joel S. Perlmutter has received research funding from National Institutes of Health NS075321, NS103957, NS107281, NS092865, U10NS077384, NS097437, U54NS116025, U19 NS110456, AG050263, AG‐64937, NS097799, NS075527, ES029524, NS109487, R61 AT010753, (NCATS, NINDS, NIA), RO1NS118146, R01AG065214, Department of Defense (DOD W81XWH‐217‐1‐0393), Michael J Fox Foundation, Barnes‐Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), American Parkinson Disease Association (APDA) Advanced Research Center at Washington University, Greater St. Louis Chapter of the APDA, Paula and Rodger Riney Fund, Jo Oertli Fund, Huntington Disease Society of America, Murphy Fund, and CHDI. He co‐directs the Dystonia Coalition, which received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke, TR 001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). Dr. Perlmutter has provided medical legal consultation to Wood, Cooper, and Peterson, LLC and to Simmons and Simmons LLP. He serves as Director of Medical and Scientific Advisory Committee of the Dystonia Medical Research Foundation, Chair of the Scientific Advisory Committee of the Parkinson Study Group, Chair of the Standards Committee of the Huntington Study Group (honoraria for this one), member of the Scientific Advisory Board of the APDA, Chair of the Scientific and Publication Committee for ENROLL‐HD (honoraria from this one), and member of the Education Committee of the Huntington Study Group (honoraria from this one). Dr. Perlmutter has received honoraria from CHDI, Huntington Disease Study Group, Parkinson Study Group, Beth Israel Hospital (Harvard group), U Pennsylvania, Stanford U.; Boston University.
Funding Information:
Meghan C. Campbell receives research support from NIH (NS097437, NS075321‐02, NS097799, AG063974, AT010753‐01, AT010753‐02S1), the McDonnell Center for Systems Neuroscience, the Mallinckrodt Institute of Radiology at WUSTL, the Neurimaging Labs Innovation Award, and honoraria from the Parkinson Foundation.
Funding Information:
The authors gratefully acknowledge the funding support provided by grants from NINDS (NS097437, NS075321, NS41509, NS058714, NS48924, P30 NS048056) and NIH NCRR (UL1RR024992); American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; Oertli Fund; Paula & Rodger Riney Fund; Barnes Jewish Hospital Foundation (BJHF) (Elliot Stein Family Fund & PD Research Fund) for this work. The authors gratefully acknowledge the funding support provided by grants from NINDS (NS097437, NS075321, NS41509, NS058714, NS48924, P30 NS048056) and NIH NCRR (UL1RR024992); American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; Oertli Fund; Paula & Rodger Riney Fund; Barnes Jewish Hospital Foundation (BJHF) (Elliot Stein Family Fund & PD Research Fund) for this work. We also thank the study participants for their time and effort to aid our understanding of Parkinson disease. We also thank the study coordinators and research nurse coordinators at Washington University School of Medicine, Phil Lintzenich, Thomas Belcher, Jenny Zhen-Duan, Anja Pogarcic, My Vu, Jenny Petros, Barb Merz, Katharine Cummings, Selma Avdagic, Kelly McVey, Andrea Slavik, Chris Waller, Jake Wolf, and especially Johanna Hartlein, for assistance with data collection. Finally, we acknowledge that Washington University is located on the traditional and ancestral lands of the Wazhazhe Manzhan (Osage), Myaamia (Miami), and Oc?eti S?ak?wi??(Sioux) peoples. We express our gratitude for the ancestors and recognize them as the original stewards of the land upon which Washington University resides.
Publisher Copyright:
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2021/8
Y1 - 2021/8
N2 - Objective: To examine specific symptom progression patterns and possible disease staging in Parkinson disease clinical subtypes. Methods: We recently identified Parkinson disease clinical subtypes based on comprehensive behavioral evaluations, “Motor Only,” “Psychiatric & Motor,” and “Cognitive & Motor,” which differed in dementia and mortality rates. Parkinson disease participants (“Motor Only”: n = 61, “Psychiatric & Motor”: n = 17, “Cognitive & Motor”: n = 70) and controls (n = 55) completed longitudinal, comprehensive motor, cognitive, and psychiatric evaluations (average follow-up = 4.6 years). Hierarchical linear modeling examined group differences in symptom progression. A three-way interaction among time, group, and symptom duration (or baseline age, separately) was incorporated to examine disease stages. Results: All three subtypes increased in motor dysfunction compared to controls. The “Motor Only” subtype did not show significant cognitive or psychiatric changes compared to the other two subtypes. The “Cognitive & Motor” subtype’s cognitive dysfunction at baseline further declined compared to the other two subtypes, while also increasing in psychiatric symptoms. The “Psychiatric & Motor” subtype’s elevated psychiatric symptoms at baseline remained steady or improved over time, with mild, steady decline in cognition. The pattern of behavioral changes and analyses for disease staging yielded no evidence for sequential disease stages. Interpretation: Parkinson disease clinical subtypes progress in clear, temporally distinct patterns from one another, particularly in cognitive and psychiatric features. This highlights the importance of comprehensive clinical examinations as the order of symptom presentation impacts clinical prognosis.
AB - Objective: To examine specific symptom progression patterns and possible disease staging in Parkinson disease clinical subtypes. Methods: We recently identified Parkinson disease clinical subtypes based on comprehensive behavioral evaluations, “Motor Only,” “Psychiatric & Motor,” and “Cognitive & Motor,” which differed in dementia and mortality rates. Parkinson disease participants (“Motor Only”: n = 61, “Psychiatric & Motor”: n = 17, “Cognitive & Motor”: n = 70) and controls (n = 55) completed longitudinal, comprehensive motor, cognitive, and psychiatric evaluations (average follow-up = 4.6 years). Hierarchical linear modeling examined group differences in symptom progression. A three-way interaction among time, group, and symptom duration (or baseline age, separately) was incorporated to examine disease stages. Results: All three subtypes increased in motor dysfunction compared to controls. The “Motor Only” subtype did not show significant cognitive or psychiatric changes compared to the other two subtypes. The “Cognitive & Motor” subtype’s cognitive dysfunction at baseline further declined compared to the other two subtypes, while also increasing in psychiatric symptoms. The “Psychiatric & Motor” subtype’s elevated psychiatric symptoms at baseline remained steady or improved over time, with mild, steady decline in cognition. The pattern of behavioral changes and analyses for disease staging yielded no evidence for sequential disease stages. Interpretation: Parkinson disease clinical subtypes progress in clear, temporally distinct patterns from one another, particularly in cognitive and psychiatric features. This highlights the importance of comprehensive clinical examinations as the order of symptom presentation impacts clinical prognosis.
UR - http://www.scopus.com/inward/record.url?scp=85111673702&partnerID=8YFLogxK
U2 - 10.1002/acn3.51436
DO - 10.1002/acn3.51436
M3 - Article
C2 - 34310084
AN - SCOPUS:85111673702
SN - 2328-9503
VL - 8
SP - 1695
EP - 1708
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 8
ER -